Printer Friendly

Scynexis Names Scott Sukenick as General Counsel.

M2 PHARMA-November 21, 2017-Scynexis Names Scott Sukenick as General Counsel

(C)2017 M2 COMMUNICATIONS

- Jersey City, New Jersey-based anti-infectives developer Scynexis, Inc. (NASDAQ: SCYX) has appointed Scott Sukenick, J.D., as general counsel, effective November 15, 2017, the company said.

Sukenick will be responsible for leading the company's corporate strategic and tactical legal initiatives, including intellectual property and compliance.

Sukenick joins Scynexis after over a decade addressing a diversity of legal challenges faced by innovative life sciences companies at all stages of development. He most recently worked at Cooley LLP, where he focused on life sciences litigation and strategic intellectual property management.

Prior to Cooley, he worked at Patterson Belknap Webb and Tyler LLP, where he primarily represented pharmaceutical and medical device companies in patent litigation.

He started his career at Simpson Thacher and Bartlett LLP, where his practice focused on complex commercial litigation and intellectual property transactional matters.

Sukenick is a registered patent attorney. He obtained a B.S. in Biology and a B.A. in Chemistry from Duke University and a J.D. from Harvard University.

Scynexis is committed to delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections.

The company's lead product candidate, SCY-078, is the first representative of a novel oral and IV triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 21, 2017
Words:243
Previous Article:US FDA Grants United Therapeutics Six Additional Months of Exclusivity for Adcirca.
Next Article:Promentis Pharmaceuticals Begins Ascending Dose Study of SXC-2023 for Treatment of Neuropsychiatric Disorders.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters